Man With Spontaneous Intracranial Hemorrhage on Therapeutic Enoxaparin, Clopidogrel, and Aspirin
Mihir K. Patel, MD, Sumeet K. Chhabra, MD, Michael Pfeiffer, MD

Case Presentation
A 65 year-old Caucasian male originally presented to an outside hospital complaining of worsening paroxysmal nocturnal dyspnea, orthopnea, and recent exertional chest pain associated with dyspnea. The patient’s past medical history was significant for coronary artery disease status post coronary bypass, severe aortic stenosis status post bioprosthetic aortic valve repair, congestive heart failure, atrial fibrillation on anticoagulation, dual-chamber pacemaker placement, history of a transient ischemic attack, and type 2 diabetes mellitus. At the outside hospital, coronary angiography revealed occlusion of native vessels and previous grafts. He was considered a poor surgical candidate. He was transferred to Thomas Jefferson University Hospital (TJUH) for a second opinion regarding percutaneous versus surgical intervention.

The patient’s initial hospital course was complicated by persistent volume overload treated with aggressive intravenous (IV) diuresis and atrial fibrillation refractory to medical therapy. Electrophysiology service recommended electrophoresis transesophageal echocardiogram (TEE) and electrocardioversion; TEE revealed no left atrial clot, and the procedure was successful in restoring sinus rhythm. Throughout his hospitalization, the patient was maintained on weight-adjusted therapeutic low molecular weight heparin (LMWH, enoxaparin), clopidogrel, and aspirin. Other medications included amiodarone, atorvastatin, digoxin, esomeprazole, ezetimibe, isosorbide mononitrate, metoprolol succinate (XL), spironolactone, levothyroxine, niacin, repaglinide, sertraline, and insulin.

Approximately two weeks after transfer to TJUH and two days after cardioversion, the housestaff was called overnight for an acute change in mental status and blurry vision. Upon evaluation, patient was unable to respond to questions appropriately. He complained of “not feeling well” and reported new bilateral blurry vision. The patient and nursing staff denied any recent trauma or fall. He was afebrile, normotensive (10/70) with normal sinus rhythm (60 bpm), saturating well (98%) in no respiratory distress (18 resp/minute) with finger-stick blood glucose of 93 mg/dL. Exam revealed the patient was oriented only to person; Glasgow Coma Scale (GCS) on initial evaluation was 14. Complete neurologic exam was non-focal: pupils were equal in size and reactive to light and accommodation; visual fields were intact bilaterally; cranial nerves II-XII were intact and symmetrical; muscle strength was full in his upper and lower extremities bilaterally; and his distal upper and lower extremity sensation was intact and symmetric.

Stat head CT (Figure 1) revealed a large intraparenchymal hemorrhage in the left parietal and temporal lobes, involving the left lateral ventricle, third ventricle, and partial filling of right lateral and fourth ventricles. A 7 mm left-to-right midline shift with local mass effect is also observed.

Figure 1.
Head CT without contrast shows a large intraparenchymal hemorrhage in the left parietal and temporal lobes with extension into the ventricles. Associated 7 mm left-to-right midline shift with local mass effect is also observed.

Neurosurgery evaluated the patient and arranged transfer to the Neurological ICU for emergent right frontal ventriculostomy. Per consultation with hematology, the patient received enoxaparin-adjusted IV protamine sulfate to attempt reversal of therapeutic enoxaparin. The patient’s clopidogrel and aspirin were also discontinued. The patient remained normotensive throughout these events; however, his mental status and level of consciousness continued to deteriorate rapidly. Despite additional IV protamine sulfate, fresh frozen plasma, and factor IX, the hematoma continued to expand as demonstrated by repeat head CT (Figure 2) performed 10 hours after the initial diagnosis. Further surgical options were discussed with the
patient’s wife. Considering the low likelihood of significant functional recovery and her knowledge of the patient’s wishes, surgical options were declined. He was subsequently placed on a morphine infusion for comfort and expired the next evening.

Discussion

According to the American Stroke Association, intracerebral hemorrhages (ICH) affected an estimated 67,000 individuals in 2002, and only 20% of those individuals were expected to be functionally independent six months after the event. The 30-day mortality of an ICH is reported to be 35 to 52%, with the majority of deaths occurring within the first 2 days. Rapid recognition is critical due to the potential for quick deterioration of patients with this condition. The classic presentation is the sudden onset of a focal neurological deficit that worsens over minutes to hours. Other symptoms and signs include headache, vomiting, and decreased level of consciousness. There is usually a smooth progression of the neurological deficit over time. This progression is uncommon in ischemic strokes and subarachnoid hemorrhages. Nevertheless, clinical features alone are not sufficient to differentiate between ischemic and hemorrhagic strokes, and therefore, imaging is crucial. CT and MRI appear to be equal in detecting an ICH, as well as determining size, location, and extent of hematoma enlargement. Generally, CT is superior in detecting ventricular extension, while MRI is superior in detecting structural lesions, amount of surrounding edema, and herniation. Because of the urgency associated with a concern for ICH combined with the availability and duration of MRI scans, CT is more commonly obtained.

Other aspects of the initial evaluation include obtaining vital signs, laboratory studies, an EKG, and a chest x-ray. In a study conducted by the Spanish Neurological Society, a temperature greater than 37.5°C, an elevated serum neutrophil count, and an elevated fibrinogen level were all associated with early neurological deterioration.

Patients diagnosed with an ICH need ICU level care along with neurosurgical evaluation or transfer to a facility with neurosurgical capabilities. The major aspects of medical management for ICH involve controlling blood pressure, decreasing intracranial pressure, and treating associated conditions, such as hyperthermia, concomitant infections, or hyperglycemia. Any anticoagulation should be immediately discontinued or reversed if possible. Treating fevers with antipyretics is valuable because lower body temperature lessens tissue damage by redistributing oxygen and decreases glucose consumption to permit relative tolerance to oxygen deprivation. The data for treating hyperglycemia has been extrapolated from the data on ischemic strokes. Hyperglycemia in the first 24 hours (>140 mg/dL) after an ICH is associated with worse outcomes, and current guidelines recommend the use of insulin for blood glucose levels over 140 to 185. Ongoing research should provide more specific information and clarify these guidelines.

Treatment of elevated intracranial pressures should start with simple measures such as elevating the head of the bed to thirty degrees and keeping the head in midline position. If more aggressive measures are needed, options include IV mannitol to achieve plasma osmolality of 300 to 310 mosmol/kg, barbiturate coma, or hyperventilation to a PaCO₂ of 25 to 30 mm Hg. These patients also need concomitant measuring of intracranial pressure and blood pressure. Steroids should not be used as they increase complication rates, particularly infection, and have not been shown to improve outcomes. Many clinicians also use antiepileptic agents for seizure prophylaxis. A study in Italy aimed at characterizing ICH-related seizure revealed that use of antiepileptic agents soon after ICH onset could reduce the risk of early seizures. However, this benefit has yet to be substantiated by prospective clinical studies.

There are no clear guidelines on how to manage elevated blood pressure in ICH. On one hand, lowering the blood pressure potentially slows hematoma expansion. On the other hand, lowering blood pressure can also induce cerebral ischemia in the edematous portions surrounding the hemorrhage. Current

---

**Figure 2**

On a repeat head CT performed ten hours later, there is significant expansion of the left intraparenchymal hematoma and ventricular hemorrhage, with increasing rightward midline shift. Interval placement of a right frontal ventriculostomy catheter is noted.
guidelines, as outlined in Table 1, recommend using continuous IV infusion of antihypertensive agents for SBP > 200 or MAP > 150 mm Hg, and either continuous or intermittent IV medications for SBP > 180 or MAP > 130 mm Hg. Ongoing trials are specifically evaluating the control of blood pressure in patients with ICH.¹

<table>
<thead>
<tr>
<th>Table 1. Suggested Recommended Guidelines for Treating Elevated Blood Pressure in Spontaneous ICH</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. If SBP is &gt;200 mm Hg or MAP is &gt;150 mm Hg, then consider aggressive reduction of blood pressure with continuous intravenous infusion, with frequent blood pressure monitoring every 5 minutes.</td>
</tr>
<tr>
<td>2. If SBP is &gt;180 mm Hg or MAP is &gt;130 mm Hg and there is evidence of or suspicion of elevated ICP, then consider monitoring ICP and reducing blood pressure using intermittent or continuous intravenous medications to keep cerebral perfusion pressure &gt;60 to 80 mm Hg.</td>
</tr>
<tr>
<td>3. If SBP is &gt;180 mm Hg or MAP is &gt;130 mm Hg and there is not evidence of or suspicion of elevated ICP, then consider a modest reduction of blood pressure (e.g., MAP of 110 mm Hg or target blood pressure of 160/90 mm Hg) using intermittent or continuous intravenous medications to control blood pressure, and clinically reexamine the patient every 15 minutes.</td>
</tr>
</tbody>
</table>

Recent studies are clarifying the risk of ICH and ICH-related mortality associated with anticoagulation. Due to its predictable and reproducible anticoagulant effects, LMWH has become increasingly preferred over unfractionated heparin (UFH) for anticoagulation in the inpatient setting. LMWH and UFH have similar rates of major bleeding,² yet studies comparing LMWH to UFH in patients with ST-elevation myocardial infarction who have also received thrombolytics have shown an increased risk of ICH in patients receiving LMWH over those receiving UFH.³ Predictors of anticoagulant-related ICH included coronary artery disease, atrial fibrillation, history of ischemic stroke, and history of pulmonary embolus or deep vein thrombosis. Patients with anticoagulant-related ICH also had a higher mortality rates than other ICH patients. The difference in mortality rates within the first 24 hours post event in one retrospective review was 33.2% in anticoagulant-related ICH versus 16.3% in patients with ICH not on anticoagulation.⁴ Anti-platelet therapy is also associated with worse clinical outcomes and is an independent predictor for acute hematoma enlargement, rapid death, and need for emergent hematoma evacuation.⁵

There is no proven method for reversing the effects of LMWH. Unfractionated heparin and LMWH exert their effects by binding to and catalyzing antithrombin III, which inhibits certain coagulation factors, particularly factor IIa and factor Xa. LMWH has a reduced ability to inhibit factor IIa compared to UFH, but has a similar effect on factor Xa. Intravenous protamine in animal studies and in vitro studies significantly neutralizes the factor IIa activity of LMWH, but only neutralizes 60% of its anti-factor Xa activity. Moreover, studies demonstrating or refuting protamine’s beneficial effect on LMWH-related bleeding in humans are lacking. Nevertheless, in a patient who received LMWH within an 8 hour time window, the recommended approach is to administer 1 mg of IV protamine for every 100 anti-factor Xa units of LMWH. One milligram of enoxaparin is equal to 100 anti-factor Xa units. Therefore, a patient who received 80 mg of subcutaneous enoxaparin within 8 hours should be given 80 mg of IV protamine. A second dose of 0.5 mg of IV protamine per 100 anti-factor Xa units may be given if bleeding continues. If LMWH was administered more than 8 hours ago, a lower initial dose of protamine is recommended. For UFH, 1 mg of IV protamine will neutralize 100 units of UFH.⁶

Conclusion
In summary, we have presented a case of severe intracerebral hemorrhage in a patient receiving therapeutic enoxaparin and antiplatelet agents. Initial suspicion for acute intracranial hemorrhage was low based on non-localizing neurological exam and lack of head trauma, but remained within the immediate differential given the patient’s history and current medications. The patient exhibited signs of slow global neurologic deterioration, but his exam remained non-focal throughout his hospital course. In this instance, radiographic evaluation was pursued promptly. Although the intent was to rule out, rather than confirm, suspected intracranial pathology, radiographic imaging remained an integral part of the complete patient evaluation.

Our experience suggests that while ICH classically presents with focal deficits, the absence of focal deficits does not exclude the diagnosis. It should remain high on any physician’s differential while caring for a patient with an acute mental status change, particularly in a patient on therapeutic anticoagulation or antiplatelet medications. In managing patients with an ICH, prompt neurosurgical evaluation is required. Additional immediate attention should focus on controlling hypertension, elevated intracranial pressure, hyperthermia, and hyperglycemia; reversing anticoagulants if needed; and monitoring the patient in an intensive care unit.

References


